Brief intro:
- Author: Suin Jo, Lijin Li, Chandrani Thakur, Kevin A. Telfer, Hussein Sultan, Ray A. Ohara, Michelle He, Giri Nam, Jing Chen, Feiya Ou, Monia Draghi, Nicholas M. Valiante, Robert D. Schreiber, Gwendalyn J. Randolph, Naresha Saligrama, Theresa L. Murphy, William E. Gillanders & Kenneth M. Murphy
- Journal: Nature
- Doi: https://www.doi.org/10.1038/s41586-026-10353-6
- Publication Date: 2026/4/15
Abstract
Vaccines composed of mRNA and lipid nanoparticles (LNPs) activate B cells and T cells by inducing in vivo production of specific protein antigens. While B cells can be activated directly by antigens, T cell activation requires antigen processing and presentation by MHC molecules on specialized antigen-presenting cells (APCs). In response to viral infections, tumours, and protein- and cDNA-based vaccines, antigen presentation to CD8+ T cells is particularly dependent on type 1 conventional dendritic (cDC1) cells, which are specialized for efficient cross-presentation of exogenous antigens1,2,3,4. However, whether similar mechanisms have a role in mRNA–LNP vaccination is unclear. Here we report that mRNA–LNP vaccines do not require cDC1 cells or the WDFY4-dependent cross-presentation pathway for CD8+ T cell priming but instead engage both cDC1 and cDC2 cells redundantly. While CD8+ T cells primed exclusively by either cDC1 or cDC2 cells showed phenotypic differences, both could mediate anti-tumour responses and memory formation. Importantly, acquisition by cDCs of peptide–MHC-I complexes from non-haematopoietic cells, called cross-dressing, provides a substantial component of CD8+ T cell priming, in a manner dependent on type I interferon. mRNA–LNP induction of cross-dressing might explain their ability to activate CD8+ T cells against antigens not encoded by the vaccine.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.